Page 2438 - Williams Hematology ( PDFDrive )

2409
2408 Index Index 2409

Camptotheca acuminata, 326 Cangrelor, 404t, 405, 2076 erythrocytosis and, 871, 872, 876, 881
Camptothecins, 319t, 326–328 CANNTG (consensus E-box motifs), 262 fibrinolytic system in, 1974–1976, 1974t,
Campylobacter, 820, 1212, 1216, 1574, 1664 Cao Gio, 2107 1975f
Campylobacter jejuni, 1790 CAPS (catastrophic antiphospholipid heart valve hemolysis, 804–806, 805t, 806f
CAMT (congenital amegakaryocytic syndrome), 2239, 2245 hemochromatosis and, 642
thrombocytopenia), 530t, 532, CapZ, 1833t, 1839f, 1840 in hemolytic uremic syndrome, 2259
1822 CAR (chimeric antigen receptor), 415–416, in hemophilia, 2130
Canale-Smith syndrome. See Autoimmune 415f, 438, 442, 454, 1193 hereditary thrombophilia and, 2226–2227
lymphoproliferative syndrome Carbamazepine, megaloblastic anemia and, history of, 5
(ALPS) 606t Hodgkin lymphoma treatment and, 1618
cANCA (cytoplasmic antineutrophil Carbohydrates monocytes/macrophages in, 1079
cytoplasmic antibody), 1013 antigens, 2337, 2338f myocardial infarction. See Myocardial
Cancer. See also individual types in erythrocytes, 471t infarction (MI)
ataxia-telangiectasia and, 1226–1227 loading, for acute intermittent porphyria, neutrophilia and, 1001
cellular senescence and, 132 904 primary lymphoma, 1581
chemotherapy. See Antineoplastic drugs/ metabolism in neutrophils, 932 red cell transfusion in, 6–7, 2370t
chemotherapy Carbonic anhydrase I, 701t regenerative therapies for, 450
disseminated intravascular coagulation in, Carbonic anhydrase II, 701t risk factors, 2281–2282, 2282t, 2288
803–804, 2207–2208 Carbon monoxide (CO), in red cell life span in sickle cell disease, 769
HIV-associated. See Human measurement, 496 thrombophilia testing in, 2228–2229
immunodeficiency virus Carbon monoxide poisoning in thrombotic thrombocytopenic purpura,
(HIV)–associated malignancies clinical and laboratory features, 795 2255
immune cell therapy. See Immune cell epidemiology, 795 vulnerability to, 2289–2291, 2290f, 2291t.
therapy (adoptive cellular therapy), etiology and pathogenesis, 795 See also Atherosclerosis
of malignancy therapy, course, and prognosis, 795–796 Carfilzomib, 342–343, 342f
lymphocytosis and, 1204 Carbonyl iron, 638 mechanism of action, 241
marrow infiltration in, 658, 659f Carboplatin for myeloma, 1750–1751, 1753t, 1754
microangiopathic hemolytic anemia and, adverse effects, 330 for Waldenström macroglobulinemia, 1794
803–804, 803t for diffuse large B-cell lymphoma, 1629t, Carmustine (BCNU)
monocytosis and, 1097 1631 aplastic anemia and, 516
neutrophilia and, 1001 high-dose, 331t, 332t for diffuse large B-cell lymphoma, 1632
next-generation sequencing analysis, for Hodgkin lymphoma, 1616 doses and toxicities, 331, 332t, 368
160–161 pharmacology, 330 in hematopoietic cell transplantation
thrombotic microangiopathy in, 2262 Carboxyhemoglobin, 795–796 conditioning, 360
vaccine therapy for. See Vaccine therapy Carbromal, 830 for Hodgkin lymphoma, 1616
venous thromboembolism in, 2276–2277 CARD (caspase activation and recruitment for mycosis fungoides, 1685
Candida infections domain), 205, 298–299, 1025, 1054, platelet function and, 2079
acute myelogenous leukemia treatment 1230 Carotid endarterectomy, 2297
and, 1410 CARD9, 1230 Carrier, 147
in chronic granulomatous disease, 1021 CARD11, 233t, 235t, 236t Carrión disease, 818
disseminated, 2104–2105, 2105f Cardiacos negros, 871 CAR-T (chimeric antigen receptor T) cells,
after hematopoietic cell transplantation, Cardiac output, anemia and, 505 1539
1182 CARDIF. See Mitochondrial antiviral Cartilage hair hypoplasia, 993, 1226
in hyperimmunoglobulin E syndrome, signaling protein (MAVS) Caspase activation and recruitment domain
1026, 1225 Cardiolipin, 1955 (CARD), 205, 298–299, 1025, 1054,
in immunocompromised host, 383 Cardiopulmonary bypass, 2085–2086, 2318, 1065f, 1230
in Langerhans cell histiocytosis, 1104 2384 Caspases
in leukocyte adhesion deficiency, 1023 Cardiovascular disease. See also Vascular activation, 204–205, 204f, 1065f
in newborn, 106 disease/injury in apoptosis, 203–204
pattern-recognition signaling defects with in acute myelogenous leukemia, 1381, in lymphoma, 210
increased susceptibility to, 1230 1410 in T-cell therapy, 416
prevention, 389 in AL amyloidosis, 1760, 1761, 1775, Caspofungin, 385, 388t, 389
red cell antigens and susceptibility to, 2340 1775t, 1777–1779, 1778f, 1780f, Castleman disease, 1249–1250, 1496t, 1573
in specific granule deficiency, 1021 1781 Catalase, 286
Th17 T cells and, 369 anthracycline-induced, 1520 abnormalities, 701t
treatment, 385 in antiphospholipid syndrome, 2240 activity, 692t

Kaushansky_index_p2393-2506.indd 2409 9/21/15 3:21 PM